Omega Funds

Funding rounds backed by Omega Funds.

Export CSV
Funding disclosed in full
$308.5M
Median round
$59.5M
Rounds in calculation
4
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
Vaderis Therapeutics

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

$152MSeries BBiotechSwitzerland
8 participantsDroiaEQT Life SciencesGoldman Sachs AlternativesKalehua CapitalMedicxiOmega FundsPerceptive AdvisorsTCGX
Third Arc Bio

Develops novel multifunctional antibodies for oncology and immunology & inflammation indications

$52MSeries A+BiotechUnited States
11 participantsAbbVie VenturesabrdnAlderline GroupAndreessen Horowitz (a16z)BVF Partners LPGalapagos NVGoldman Sachs Alternatives Life SciencesHillhouse InvestmentMarshall WaceOmega FundsT. Rowe Price Associates
Caldera Therapeutics

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1BiotechUnited States
5 participantsJanus Henderson InvestorsLAVOmega FundsvenBioWellington Management
Spiro Medical

Develops a Pulmonary Neuromodulation System for asthma treatment

$67MSeries AHealthtechUnited States
7 participantsAndera PartnersHero IncHSGNorthern Light Venture CapitalOmega FundsSherpa Healthcare PartnersSupernova Invest